Sleep apneas are present in patients with obstructive sleep apnea syndrome (OSAS). These apneas cause a decrease in arterial oxygen saturation (SaO~2~) and tissue hypoxia. Reoxygenation follows the termination of apneas. This cycle causes the evolution of hypoxic oxidative stress (HOS). Because of HOS, the production of ATP (adenosine triphosphate) from ADP (adenosine diphosphate) is impaired, leading to a net degradation of ATP to ADP and adenosine monophosphate. This cascade leads to the release of inter-mediates of purine nucleotide (adenosine, inosine, hypoxanthine, and xanthine).[@b1-asm-1-37] Uric acid (UA) is biosynthesized from these purine catabolic products. HOS triggers exaggerated degradation of glucose through the glycolytic pathway, resulting in an accumulation of pyruvate.[@b2-asm-1-37] Lactate dehydrogenase converts accumulated pyruvate to lactate. The lack of ATP in a state of hypoxemia markedly impairs the utilization of lactate by a process of gluconeogenesis in the liver (Cori cycle) and renal cortex. Thus tissue hypoxia results in hyperlactemia and lactic acidosis.[@b3-asm-1-37],[@b4-asm-1-37] Therefore, hyperuricemia and hyperlactemia are markers of tissue HOS in OSAS patients.

Conditions such as infant respiratory syndrome, strenuous exercise, hypotension, acute respiratory distress syndrome, and critical illness cause a raised level of UA in the human body.[@b5-asm-1-37]--[@b9-asm-1-37] Both ischemia and hypoxia are responsible for the higher level of UA in these entities. However, no study exists to show the measurement of both serum UA and plasma lactate levels simultaneously in OSAS patients, prompting us to undertake this study.[@b10-asm-1-37] Various studies have experimentally and clinically shown that inadequate oxygen delivery to maintain tissue oxygenation elevates the serum lactate level.[@b11-asm-1-37]--[@b17-asm-1-37] Studies related to the measurement of the serum lactate level in OSAS patients are very few. In 2009, Ucar et al[@b18-asm-1-37] demonstrated a relationship between nocturnal hypoxia and arterial lactate levels in sleep-related breathing disorders.

PATIENTS AND METHODS
====================

This was a case-control study that included 40 OSAS patients and 40 control (healthy) subjects. The institutional academic board and ethical committee approved the protocol of the study. All participants gave informed written consent. All subjects underwent overnight polysomnography (PSG), using VIASYS Healthcare Sleep Screen Apnea Screen Cardio Polysomnography (VIASYS Healthcare, Germany) equipment for the duration of 6--8 hours. The parameters recorded by PSG included central electroencephalography (C3/A2 and C4/A1), electrooculography, submental electromyography, anterior tibialis electromyography, electrocardiography, continuous-pulse oximetry, thoracic and abdominal movements, and oro-nasal airflow. The period for which patients underwent PSG was recorded as TST (total sleep time) spent. The percentage of total sleep time spent (%TST) below 95%, 90%, and 85% of SaO~2~ was recorded.

A decrease in inspiratory flow to less than 20% of waking level for at least 10 seconds was considered apnea. The presence of more than 5 apneas per hour of sleep established the diagnosis of OSAS. A decrease in inspiratory airflow to \<50% of waking level was considered hypopnea. The apnea-hypopnea index (AHI) was the average of the total number of apneas and hypopneas per hour of TST. The grading of severity of OSAS was based on AHI. OSAS was considered mild (AHI, 5--10), moderate (AHI. 10--30), or severe (AHI, \>30). Forty subjects with no apnea or less than 20 apneas during 6--8 hours (TST) of sleep were taken as healthy controls.

Over a period of 1 year, physicians referred 64 patients with suspected OSAS to the Sleep Laboratory of the Department of Pulmonary Medicine. Based on criteria, a history of loud snoring and excessive daytime sleepiness, 40 patients suffering from OSAS were selected. Forty persons in whom overnight PSG ruled out OSAS were included as healthy subjects (controls). To eliminate confounding effects, inclusion of patients and controls was based on matching of age and sex, and presence of obesity ([Table 1](#t1-asm-1-37){ref-type="table"}). All participants of the study underwent anthropometry and biochemical tests. Anthropometry included measurement of height, weight, waist, and neck circumference and waist-hip ratio (WHR), using standardized techniques. The body mass index (BMI) was calculated. On the basis of BMI, OSAS patients were categorized as normal, overweight, obese, or morbid obese ([Table 1](#t1-asm-1-37){ref-type="table"}).

Two samples of peripheral arterial blood of all participants were drawn; the first one drawn before beginning the PSG and second one at the end of PSG. Immediately, blood was transported to the biochemical- genetic laboratory for estimation of lactate in a fluorized tube and UA in a plain glass bottle.

The serum lactate was measured using a lactate pap fluid mono-reagent kit (Centronic GmbH, Wattenberg, Germany), and was analyzed on double- beam UV-VIS spectrophotometer UV5704SS (Electronic Co. of India Ltd., India) analyzer. The serum UA was measured using an auto-analyzer.

SPSS (version 14) software (SPSS, Inc, Chicago, IL) was used to analyze the data. The nonparametric Mann-Whitney U test was performed to analyze both serum UA and lactate variables in OSAS patients and controls ([Table 2](#t2-asm-1-37){ref-type="table"}). The unpaired *t* test and *P* values helped to compare variables between the OSAS patients and controls. Because the common variance assumption required by the *t* test was not appropriate for some of the measurements, the nonparametric analysis using the Mann-Whitney U test assessed the significance of differences. The Wilcoxon nonparametric analysis for paired parameters tested the significance of overnight changes in the serum UA and plasma lactate levels in both patients and controls; the difference between parameters was considered statistically significant with *P* value of \<.05. PSG variables, as well as serum levels of UA and lactate, among patients with OSAS were correlated ([Table 3](#t3-asm-1-37){ref-type="table"}). To observe the independent effects of age, BMI, and WHR on such correlations, multiple linear regression models were used and variables were examined ([Tables 4](#t4-asm-1-37){ref-type="table"}[](#t5-asm-1-37){ref-type="table"}--[6](#t6-asm-1-37){ref-type="table"}).

RESULTS
=======

Statistically significant differences were not observed in age, sex, and BMI between OSAS patients and controls ([Table 1](#t1-asm-1-37){ref-type="table"}). However, OSAS patients had greater waist circumference (*P*=.03) and neck circumference (*P*=.001) as compared to controls. No statistically significant differences were recorded between the weights and WHPs of both groups. Comparing BMI between OSAS patients and controls revealed that obesity had a greater central fat distribution among patients as compared to controls. On the basis of AHI, OSAS was mild in 6 patients, moderate in 6, and severe in 28.

The mean serum level of UA in OSAS patients was 7.54 (1.63) mg/dL and 7.66 (2.1) mg/dL before and after sleep, respectively ([Table 2](#t2-asm-1-37){ref-type="table"}); both these values were higher than the laboratory standard reference value of 7 mg/dL. In the control group, the mean serum UA level was 5.38 (1.12) mg/dL and 5.30 (1.43) mg/dL before and after sleep, respectively ([Table 2](#t2-asm-1-37){ref-type="table"}), and this was less than the standard laboratory reference value. A statistically significant difference was observed in the mean level of serum UA between OSAS and controls before (*P*=.001) and after (*P*=.002) sleep, as computed by the nonparametric Mann-Whitney U test. Thus OSAS patients had consistently higher UA levels as compared to those of the controls, and this was independent of age, sex, and obesity. However, the Wilcoxon nonparametric analysis demonstrated no statistically significant (*P*=.8) difference between the paired UA levels before and after sleep in OSAS patients. The increase in levels of serum UA after sleep in both OSAS patients and controls (Mann-Whitney U test, *P*=.27) was not significantly different ([Table 2](#t2-asm-1-37){ref-type="table"}). Thus there was no significant overnight rise in the level of UA in OSAS patients.

Serum UA values correlated significantly with %TST below 95% SaO~2~, with a *P* value of .02, using the Pearson correlation. Although correlation was positive with %TSTs below 90% SaO~2~ and with negative with basal oxygen, these observations were not found to be statistically significant (*P*=.06), as shown in [Table 3](#t3-asm-1-37){ref-type="table"}. Moreover, the polysomnographic variables failed to show significant correlation with serum UA on respective multiple regression models controlling for age and BMI. WHR had a significant independent effect on the serum UA of OSAS patients ([Table 4](#t4-asm-1-37){ref-type="table"}). No significant correlation was found between serum UA and AHI. Thus, the OSAS group had consistently high levels of serum UA that correlated with the degree of hypoxia below 95% and 90%, and with basal SaO~2~, but WHR influenced this correlation.

The mean level of plasma lactate of OSAS patients measured before sleep was 1.74 (0.6) mmol/L and after sleep was 2.28 (0.98) mmol/L; both these values were higher than the standard laboratory reference value. In the control group, the mean serum level of plasma lactate was 1.46 (0.62) mmol/L and 1.53 (0.89) mmol/L before and after sleep, respectively; both these values were lower than the standard laboratory reference value. There was no statistically significant difference in serum levels of lactate (*P*=.2) between patients and controls before sleep. However, after sleep, the overnight rise in the lactate level was observed in OSAS patients, with statistical significance (Mann-Whitney U test, *P*=.02); while a similar overnight rise was not observed among controls (Wilcoxon analysis, *P*=.7). Thus the OSAS group had a higher basal lactate level before sleep, and the level of lactate showed a further significant overnight rise after sleep. Plasma lactate levels after sleep were correlated best with SaO~2~ below 95% (*P*=.02) and high AHI (*P*=.01). The correlation was also observed with the desaturation index of basal SaO~2~ especially when less than 90% ([Table 3](#t3-asm-1-37){ref-type="table"}). Moreover, PSG variables like AHI and less-than 95% SaO~2~ showed a significant correlation with plasma lactate on regression models controlling for age and obesity, BMI, and WHR ([Tables 5](#t5-asm-1-37){ref-type="table"}, [6](#t6-asm-1-37){ref-type="table"}). The degree of hypoxia correlated significantly with serum lactate levels and severity of OSAS; and both age and obesity did not influence the correlation.

DISCUSSION
==========

In our study, the mean level of serum UA both before and after sleep was found higher in the OSAS group as compared to that in the control group and the standard laboratory reference value; and this observation was independent of age, sex, and obesity. However, an overnight rise in serum UA levels was not observed. The raised serum UA correlated with the degree of hypoxia, but regression analysis models revealed that WHR did influence this correlation.

Previous studies showed raised serum UA levels among OSAS patients.[@b15-asm-1-37]--[@b17-asm-1-37] A retrospective cross-sectional study of 1135 patients had similar findings and revealed a significant correlation between UA levels and OSAS.[@b17-asm-1-37] Those patients with more respiratory events (AHI or respiratory event index ≥30) had higher UA levels than those with mild OSAS and healthy controls. However, this difference was not apparent in the univariate analysis of variance. Thus, UA levels had a positive correlation with the number of apneas and oxygen desaturation during sleep, but this correlation seems to be influenced by other factors, like obesity.[@b17-asm-1-37] In contrast to the above observations, in another study a relationship between the severity of sleep apnea (respiratory disturbance index and %TSTs below 89% SaO~2~) and the increased level of serum UA was found independent of abdominal obesity.[@b16-asm-1-37]

In the present study, higher levels of serum UA were independent of age, sex, and obesity of OSAS patients, but they correlated with the degree of hypoxia. There was no correlation between AHI and serum UA in the present study. This deviation from findings of earlier studies[@b17-asm-1-37] could be attributed to a smaller number of OSAS patients in the present study.

The overnight change in the serum UA level in OSAS patients was not investigated in previous studies.[@b15-asm-1-37]--[@b17-asm-1-37] We could not demonstrate that hypoxia during sleep did affect the rise in the serum UA level after sleep. The basic metabolism impaired the utilization of UA. The lack of uricase enzyme in a human body metabolized UA, which is is eliminated only by renal excretion, that is, in urine, with a half-life of 0.85 day.[@b19-asm-1-37] Thus, the slow rate of UA metabolism was attributed to the overnight change in the serum UA level in patients with OSAS.

Serum lactate is an indicator of tissue hypoxia. OSAS causes hypoxemia and tissue hypoxia during sleep, owing to apneas. In addition, conversion of pyruvate to lactate by the process of anaerobic glycolysis conversion of pyruvate to lactate occurs in the pressure of sleep-associated hypoxemia in OSAS patients. Significantly, the elevated plasma lactate levels were present in OSAS patients, but these raised levels were absent in controls. A significant correlation was found between the raised lactate levels after sleep, and the severity of OSAS and the degree of hypoxemia during sleep particularly % TST below 95% of SaO~2~. The correlation of age and obesity (BMI and WHR) with plasma lactate levels was also observed to be significant in the respective multiple regression models. Age and obesity variables could not influence plasma lactate levels. Although the mean basal lactate level (1.74 mmol/L) before sleep in OSAS patients did not differ significantly from that in healthy controls, it was higher than the standard laboratory reference value in OSAS patients. However, the correlation was not present with the desaturation index. This could be attributed to chronic daytime gaseous abnormalities present in OSAS patients.[@b20-asm-1-37]--[@b24-asm-1-37] Rapid metabolism of lactate with a half-life of 20 minutes facilitates measuring transient nighttime hypoxemia in OSAS patients. Morning lactate was demonstrated to be significantly higher in patients with sleep-related breathing disorders in a recent study.[@b18-asm-1-37] However, no such study is available in which both UA and lactate levels are carried out simultaneously in patients and healthy controls.

In conclusion, an overnight rise in the lactate level seems to be a sensitive marker of the degree of HOS in OSAS patients. The serum UA level increases in OSAS patients, probably because of its increased production. The measurement of UA is not a sensitive marker of the overnight rise owing to its slower metabolism as compared to that of lactate. The effectiveness of continuous positive airway pressure therapy in patients with OSAS may be enhanced by knowing the serum lactate level before and after night PSG, as the serum lactate level is found to be a better marker of oxidative stress among patients with OSAS.

###### 

Matching between obstructive sleep apnea syndrome patients and controls.

  Independent variables       Value                      Number of subjects   
  --------------------------- -------------------------- -------------------- ----
  Age (years)                 \<40                       10                   12
                              40 to 50                   20                   16
                              \>50                       10                   12
  Sex                         Male                       36                   36
                              Female                     4                    4
  Body mass index (kg/m^2^)   \<25 (normal)              0                    0
                              25 to 29.99 (overweight)   6                    8
                              30 to 39.99 (obese)        30                   32
                              \<40 (morbidly obese)      4                    0

###### 

Analysis of serum uric acid and lactate variables in obstructive sleep apnea syndrome patients and controls.

  Variable parameters                Group     Mean value   Standard deviation   *P* value (Mann-Whitney U test)
  ---------------------------------- --------- ------------ -------------------- ---------------------------------
  Serum uric acid before sleep (b)   Control   5.38         1.12                 .001
  OSAS                               7.54      1.63                              
  Serum uric acid after sleep (a)    Control   5.30         1.43                 .002
  OSAS                               7.66      2.10                              
  Serum uric acid change (a--b)      Control   −0.07        0.70                 .27
  OSAS                               0.18      1.07                              
  Plasma lactate before sleep (b′)   Control   1.46         0.62                 .2
  OSAS                               1.74      0.60                              
  Plasma lactate after sleep (a′)    Control   1.53         0.89                 .03
  OSAS                               2.28      0.98                              
  Plasma lactate change (a′--b′)     Control   −0.19        0.64                 .02
  OSAS                               0.56      0.94                              

a: after sleep, b: before sleep

###### 

Correlation between polysomnographic variables and serum levels of uric acid and lactate among patients with OSAS.

  Variable (n=40)                               Desaturation index                              Basal oxygen                                     95%[a](#tfn3-asm-1-37){ref-type="table-fn"}      90%[a](#tfn3-asm-1-37){ref-type="table-fn"}     AHI
  --------------------------------- ----------- ----------------------------------------------- ------------------------------------------------ ------------------------------------------------ ----------------------------------------------- -----------------------------------------------
  Serum uric acid after sleep (a)   r           0.212                                           −0.425                                           0.494^\*^                                        0.418                                           0.264
                                    *P* value   .370                                            .062                                             .027                                             .067                                            .260
  Plasma lactate after sleep (a′)   R           0.487[b](#tfn4-asm-1-37){ref-type="table-fn"}   −0.492[b](#tfn4-asm-1-37){ref-type="table-fn"}   −0.654[b](#tfn4-asm-1-37){ref-type="table-fn"}   0.553[b](#tfn4-asm-1-37){ref-type="table-fn"}   0.670[b](#tfn4-asm-1-37){ref-type="table-fn"}
                                    *P* value   .030                                            .028                                             .002                                             .011                                            .001

r: correlation coefficient for serum uric acid, R: correlation coefficient for plasma lactate, AHI:apnea-hypopnea index.

%TST below X oxygen saturation;

significant correlation after sleep

###### 

Multiple linear regression analysis of serum UA as an outcome variable (adjusted R^2^=0.38) and %TSTs below 95% SaO2 as a predictor variable (controlling for age, BMI, and WHR).

  Independent variables    Coefficient   Standard error   t       *P*
  ------------------------ ------------- ---------------- ------- -----
  Constant                 −3.74                                  
  Age (year)               0.01          0.04             0.24    .82
  BMI                      −0.04         0.06             −0.67   .51
  WHR                      10.92         3.97             2.75    .01
  %TSTs below 95% SaO~2~   0.02          0.02             1.17    .26

UA: uric acid, %TSTs:percentage of total sleep time spent, SaO~2~: arterial oxygen saturation, BMI: body mass index, WHR: waist-hip ratio.

###### 

Multiple linear regression analysis with serum lactate as an outcome variable (adjusted R^2^=0.49) and AHI as a predictor variable (controlling for age, BMI, and WHR).

  Independent variables   Coefficient   Standard error   t       *P*
  ----------------------- ------------- ---------------- ------- ------
  Constant                −2.48                                  
  Age (year)              0.03          0.02             1.40    .18
  BMI                     −0.01         0.02             −0.12   .90
  WHR                     2.83          1.51             1.86    .08
  AHI                     0.02          0.01             3.27    .005

AHI: Apnea-hypopnea index, BMI: body mass index, WHR: waist-hip ratio.

###### 

Multiple linear regression analysis with serum lactate as an outcome variable (adjusted R^2^=0.37) and %TST below 95% SaO2 as a predictor variable (controlling for age, BMI, and WHR).

  Independent variables    Coefficient   Standard error   t      *P*
  ------------------------ ------------- ---------------- ------ -----
  Constant                 −2.36                                 
  Age (year)               0.02          0.02             0.99   .33
  BMI                      0.01          0.03             0.28   .78
  WHR                      1.93          1.86             1.04   .31
  %TSTs below 95% SaO~2~   0.02          0.01             2.40   .02

%TST: percentage of total sleep time, SaO~2~: arterial oxygen saturation, BMI: body mass index, WHR: waist-hip ratio.
